Effect of Mean Platelet Volume to Platelet Count Ratio on Mortality in Peritoneal Dialysis
Table 5
The association of MPV/PC with cardiovascular mortality stratified by age in PD patients.
Model 1a
Model 2b
Model 3c
HR (95% CI)
value
HR (95% CI)
value
HR (95% CI)
value
Interaction analysis ()d
for interaction < 0.001
for interaction < 0.001
for interaction = 0.140
()
Continuous MPV/PCe
0.88 (0.80-0.98)
0.015
0.90 (0.81-0.99)
0.033
0.92 (0.84-1.02)
0.102
Quartile 1
1.0
1.0
1.0
Quartile 2
0.64 (0.39-1.06)
0.085
0.65 (0.39-1.07)
0.092
0.77 (0.45-1.30)
0.324
Quartile 3
0.46 (0.25-0.82)
0.009
0.46 (0.26-0.83)
0.010
0.55 (0.30-1.01)
0.053
Quartile 4
0.37 (0.20-0.67)
0.001
0.40 (0.22-0.74)
0.003
0.49 (0.26-0.93)
0.029
P for trend
0.003
0.008
0.089
()
Continuous MPV/PCe
0.96 (0.87-1.07)
0.471
0.97 (0.87-1.08)
0.577
1.01 (0.91-1.13)
0.802
Quartile 1
1.0
1.0
1.0
Quartile 2
0.85 (0.47-1.53)
0.591
0.90 (0.50-1.62)
0.724
1.16 (0.63-2.13)
0.643
Quartile 3
0.88 (0.52-1.50)
0.648
0.87 (0.51-1.47)
0.600
1.01 (0.57-1.76)
0.986
Quartile 4
0.96 (0.51-1.81)
0.905
1.01 (0.54-1.91)
0.968
1.50 (0.77-2.92)
0.237
for trend
0.945
0.940
0.640
MPV/PC: mean platelet volume to platelet count ratio; PD: peritoneal dialysis; CV: cardiovascular; HR: hazard ratio; CI: confidence interval. aUnadjusted model. bAdjusted for gender and body mass index. cAdjusted for model 2 covariates and Charlson comorbidity index, hemoglobin, albumin, total cholesterol, triglycerides, high-sensitivity C-reactive protein, total Kt/V, residual renal function, and the use of antiplatelet drugs. dContinuous .ePer 0.01 higher MPV/PC.
